People line up Epitalon and DSIP because both surface in sleep and longevity discussions, and in 2026 both sit on the same FDA compounding agenda with insomnia among the indications under review. The comparison is worth doing to separate a shared regulatory date from a shared mechanism — because only the first is real. The table above is the row-by-row breakdown. Below is what each row means.
Epitalon vs DSIP: the short version
Both are research peptides with preclinical evidence, no published human randomized controlled trial, no registered trial, and no approval in any major jurisdiction. Both are reviewed by the FDA compounding committee on July 24, 2026, and insomnia appears in each one’s evaluated indication. The difference is the biology: Epitalon is a pineal tetrapeptide, DSIP a sleep-associated nonapeptide. Neither is a proven sleep aid.
Evidence: both preclinical, neither in trials
What is known about either comes from cell and animal studies. Epitalon (Ala-Glu-Asp-Gly) has been studied around circadian signalling and markers of ageing; DSIP, the delta sleep-inducing peptide, around sleep onset and stress responses. Neither has a registered human trial in the major registries, and neither has a published randomized controlled trial — the bar for “this works in people.” For how we weigh these tiers, see our how we grade evidence explainer, the full Epitalon evidence and regulatory record, and the DSIP evidence and regulatory record.
Same regulatory date, different molecule
The reason these two get compared in 2026 is the calendar: both are on the July 24 agenda, and both list insomnia among the indications the committee is evaluating. That is a regulatory coincidence, not evidence that they do the same thing or work equally well. Epitalon’s research history sits in circadian and ageing biology; DSIP’s sits in sleep physiology. A head-to-head that reads the shared date as a shared endorsement is misreading the agenda.
Regulation: the same July 2026 vote
Both were removed from the FDA 503A “do not compound” list in April 2026, which did not make them compoundable. The Pharmacy Compounding Advisory Committee reviews both on July 24, 2026 — Epitalon for insomnia, DSIP for opioid withdrawal, chronic insomnia and narcolepsy. We track the meeting in the July 2026 FDA peptide meeting, explained. Neither carries a marketing authorization in the European Union, and as non-approved substances both should be treated as prohibited under anti-doping rules.
So which one, if either?
There is no sourced winner. Both are unproven in humans, neither has a registered trial, and their only firm common ground is a July 2026 regulatory review that lists insomnia for each. If a guide ranks one as the better sleep peptide, it is ranking on something other than human evidence. Watch the July 2026 vote for the next real change.
Research information only. Neither Epitalon nor DSIP is approved for human use. Talk to a licensed physician before considering any peptide.